Pyruvate Kinase Inhibitors
2 drugsAbout Pyruvate Kinase
Pyruvate Kinase (PK) is an enzyme that regulates the final step of glycolysis, converting glucose to pyruvate and producing ATP. It plays a crucial role in cellular energy metabolism.
Pyruvate Kinase is a drug target due to its role in energy production, but there is currently no genetic evidence linking it to specific diseases.
Two FDA-approved small molecule drugs, PYRUKYND and AQVESME, target Pyruvate Kinase. Both drugs are marketed by Agios Pharmaceuticals for 'other' therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Nephropathy with only 1 trials.
Top Pyruvate Kinase Drugs
Agios Pharmaceuticals is the only company with approved drugs targeting Pyruvate Kinase.
High market concentration indicates potential entry barriers; consider partnership or novel approach.
Pyruvate Kinase Drug Modality Landscape
Modalities
Routes of Administration
Pyruvate Kinase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like biologics to differentiate from existing therapies.
Pyruvate Kinase Clinical Trials 16 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 | 100% |
| Phase 2 | 4 | 0 | 1 | 3 | 0% |
| Phase 3 | 7 | 1 | 0 | 6 | 100% |
| Phase 4 | 1 | 0 | 0 | 0 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pyruvate Kinase Drug Approval Timeline (2022 - 2022)
The first drug targeting Pyruvate Kinase was approved in 2022, with the most recent approval also in 2022.
Recent approvals suggest renewed interest, but rapid succession may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 70 clinical trials targeting Pyruvate Kinase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities